Hypoglycemic effect and mechanism of a proteoglycan from Ganoderma Lucidum on streptozotocin-induced type 2 diabetic rats

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 2, 2012, Pages 166-175

  Teng, B S ^a   Wang, C D ^a   Zhang, D ^b   Wu, J S ^b   Pan, D ^a   Pan, L F ^a   Yang, H J ^b   Zhou, P ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Ganoderma lucidum; Metabolic disorders; Protein tyrosine phosphatase 1B; Proteoglycan; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; FATTY ACID; FUDAN YUEYANG GANODERMA LUCIDUM EXTRACT; GANODERMA LUCIDUM EXTRACT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEOGLYCAN; ROSIGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENZYME ACTIVITY; GANODERMA LUCIDUM; GLUCOSE BLOOD LEVEL; IMMUNOPRECIPITATION; INSULIN BLOOD LEVEL; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIVER; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REVIEW; SKELETAL MUSCLE; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ARTICLE; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; EXPERIMENTAL DIABETES MELLITUS; FRUITING BODY; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; FRUITING BODIES, FUNGAL; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; LIVER; MALE; METFORMIN; MUSCLE, SKELETAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; PROTEOGLYCANS; RATS; RATS, SPRAGUE-DAWLEY; REISHI; THIAZOLIDINEDIONES;

EID: 84859506207     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. WORLD HEALTH ORGANIZATION. 10 facts about diabetes. Available from: http://www.who.int/features/factfiles/diabetes/10-en. html [Accessed June 15, 2008].
2. LENG Y, KARLSSON HK, ZIERATH JR. Insulin signaling defects in type 2 diabetes. Rev Endocr Metab Dis 2004;5:111-117. (Pubitemid 39012109)
3. NEWSHOLME EA, DIMITRIADIS G. Integration of biochemical and physiologic effects of insulin on glucose metabolism. Exp Clin Endocr Diab 2001;109:122-134.
4. ASANTE-APPIAH E, KENNEDY BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol-Endocr Metab 2003;284:663-670.
5. ELCHEBLY M, PAYETTE P, MICHALISZYN E, CROMLISH E, COLLINS S, LOY AL. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544-1548.
6. VAN-HUIJSDUIJNEN RH, BOMBRUN A, SWINNEN D. Selecting protein tyrosine phosphatases as drug targets. Drug Discov Today 2002;7:1013-1019. (Pubitemid 35304571)
7. HONG KJ, DUNN DM, SHEN CL, PENCE BC. Effects of Ganoderma lucidum on apoptotic and anti-inflammatory function in HT-29 human colonic carcinoma cells. Phytother Res 2004;18:768-770. (Pubitemid 39481699)
8. SUN J, HE H, XIE BJ. Novel antioxidant peptides from fermented mushroom Ganoderma lucidum. J Agric Food Chem 2004;52:6646-6652.
9. YUE GL, FUNG K P, LEUNG PC, LAU CS. Comparative studies on the immunomodulatory and antitumor activities of the different parts of fruiting body of Ganoderma lucidum and Ganoderma Spores. Phytother Res 2008;22:1282-1291.
10. SETO SW, LAM T Y, TAM HL, AU A L S, CHAN SW, WU JH, YU P H F, LEUNG G P H, NGAI SM, YEUNG J H K, LEUNG PS, LEE S M Y, KWAN YW. Novel hypoglycemic effects of Ganoderma lucidum water-extract in obese/diabetic (+db/+db) mice. Phytomedicine 2009;16:426-436.
11. MOHAMMED A, ADELAIYE AB, ABUBAKAR MS, ABDURAHMAN EM. Effects of aqueous extract of Ganoderma lucidum on blood glucose levels of normoglycemic and alloxan-induced diabetic Wistar rats. J Med Plants Res 2007;1:34-37.
12. LI ZB, LIU J, ZHAO Y F. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Biochem Mol Biol 2005;38:34-40. (Pubitemid 43025976)
13. HIKINO H, ISHIYAMA M, SUZUKI Y, KONNO C. Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies. Planta Med 1989;55:423-428. (Pubitemid 19249810)
14. TENG BS, WANG CD, YANG HJ, WU JS, ZHANG D, ZHENG M, FAN ZH, PAN D, ZHOU P. A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) Karst and its hypoglycemic potency on streptozotocininduced type 2 diabetic mice. J Agric Food Chem 2011;59:6492-6500.
15. MASUKO T, MINAMI A, IWASAKI N, MAJIMA T, NISHIMURA SI, LEE YC. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Anal Biochem 2005;339:69-72. (Pubitemid 40342680)
16. TAGAMI S, SAKAUE S, HONDA T, YOSHIMURA H, HOMMA H, OHNO K, NISHIMURA M, IDE H. Effects of troglitazone on skeletal muscle and liver protein tyrosine phosphatase activity in insulin-resistant Otsuka Long-Evans Tokushima fatty rats. Curr Ther Res Clin E 2002;63:572-586.
17. AHMAD F, GOLDSTEIN BJ. Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus. Metabolism 1995;44:1175-1184. (Pubitemid 26084039)
18. ANDREW P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 2010;53:2333-2344.
19. FUKUDA S, OHTA T, SAKATA S, MORINAGA H, ITO M, NAKAGAWA Y, TANAKA M, MATSUSHITA M. Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JT-551. Diabetes Obes Metab 2010;12:299-306.
20. LU YX, ZHANG Q, LI J, SUN YX, WANG LY, CHENG WM, YANG HX. Antidiabetic effects of total flavonoids from litsea coreana leve on fat-fed, streptozotocin-induced type 2 diabetic rats. Am J Chinese Med 2010;38:713-725.
21. WU Y, OU-YANG J P, WU K, WANG Y, ZHOU Y F, WEN C Y. Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B. Acta Pharmacol Sin 2005;26:345-352. (Pubitemid 40388072)
22. REED MJ, MESZAROS K, ENTES LJ, CLAYPOOL MD, PINKETT JG, GADBOIS TM, REAVEN GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocintreated rat. Metabolism 2000;49:1390-1394.
23. ELSNER M, GULDBAKKE B, TIEDGE M, MUNDAY R, LENZEN S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia 2000;43:1528-1533. (Pubitemid 32734859)
24. MATVEYENKO AV, DRY S, COX HI, MOSHTAGHIAN A, GURLO T, GALASSO R, BUTLER AE, BUTLER PC. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes interactions with metformin. Diabetes 2009;58:1604-1615.
25. EIDI A, EIDI M, ESMAEILI E. Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine 2006;13:624-629. (Pubitemid 44666394)
26. AKHANI S P, VISHWAKARMA SL, GOYAL RK. Anti-diabetic activity of Zingiber officinale in streptozotocin-induced type I diabetic rats. J Pharma Pharmacol 2004;56:101-105. (Pubitemid 38195334)
27. SHIRWAIKAR A, RAJENDRAN K, BARIK R. Effect of aqueous bark extract of Garuga pinnata Roxb. in streptozotocin-nicotinamide induced type-II diabetes mellitus. J Ethnopharmacol 2006;107:285-290. (Pubitemid 44247439)
28. SWANSTON-FLAT SK, DAY C, BAILEY CJ, FLATT PR. Traditional plant treatment for diabetes: studies in normal and streptozotocin diabetic mice. Diabetologia 1990;33:462-464. (Pubitemid 20254867)
29. ADENEYE AA, AGBAJE EO. Hypoglycemic and hypolipidemic effects of fresh leaf aqueous extract of Cymbopogon citrates Stapf. in rats. J Ethnopharmacol 2007;112:440-444. (Pubitemid 47023034)
30. BIERMAN EL, AMARAL J A P, BELKNAP BH. Hyperlipidemia and diabetes mellitus. Diabetes 1966;15:675-679.
31. SAENZ A, FERNANDEZ-ESTEBAN I, MATAIX A, AUSEJO M, ROQUE M, MOHER D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Db Syst Rev 2005;20:3-3.
32. MIYAZAKI Y, DE FRONZO RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204-1211.